Procalcitonin Use in Pneumonia Patients in the Critical Care Setting
- Conditions
- Pneumonia
- Interventions
- Other: Use of procalcitonin as biomarker to guide therapy
- Registration Number
- NCT01788488
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The goal of the study is to determine the impact of procalcitonin (PCT)-guided therapy on duration of antibiotic therapy in critical care unit (CCU) patients with suspected pneumonia at Mayo Clinic Health System Eau Claire.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 134
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Procalcitonin-guided therapy Use of procalcitonin as biomarker to guide therapy Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
- Primary Outcome Measures
Name Time Method Length of antibiotic therapy Indefinite Participants will be followed for the entire time they are on antibiotics to treat pneumonia, an expected average of 30 total antibiotic days.
- Secondary Outcome Measures
Name Time Method Length of stay in critical care unit Indefinite Participants will be followed for their entire length of stay in the critical care unit, an expected average of 7 days.
Cost Once The average cost of antibiotics per patient, measured in US dollars, based on total antibiotic days.
Length of stay in the hospital Indefinite Participants will be followed their entire length of stay in the hospital, an expected average of 14 days.
Trial Locations
- Locations (1)
Mayo Clinic Health System Eau Claire
🇺🇸Eau Claire, Wisconsin, United States